Crossmark

Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer

Crossref DOI link: https://doi.org/10.1007/s10637-014-0161-y

Published Online: 2014-09-23

Published Print: 2015-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mukai, Hirofumi

Saeki, Toshiaki

Shimada, Ken

Naito, Yoichi

Matsubara, Nobuaki

Nakanishi, Tadashi

Obaishi, Hiroshi

Namiki, Masayuki

Sasaki, Yasutsuna
License Information

Text and Data Mining valid from 2014-09-23

Version of Record valid from 2014-09-23
More Information

Article History

Received: 9 July 2014

Accepted: 8 September 2014

First Online: 23 September 2014

Document is current

Any future updates will be listed below